AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Anthony Mato, MD, MSCE, reported a financial interest/relationship or affiliation in the form of Consulting or advisory role: AbbVie, Acerta Pharma/Astra Zeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. and Verastem Inc. Grant/Research support: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Loxo Oncology, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., Regeneron Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc. Data and safety monitoring board: AbbVie, Acerta Pharma/AstraZeneca, Adaptive Biotechnologies, Celgene Corporation, DTRM Biopharma Co. Ltd., Genentech, Inc., Genmab A/S, Johnson & Johnson Services, Inc., Nurix Therapeutics, Inc., Octapharma Plasma, Inc., Pharmacyclics, Inc., TG Therapeutics, Inc Sunesis Pharmaceuticals, Inc. and Verastem Inc.
Toby A. Eyre, MD, MBChB, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie, AstraZeneca, BeiGene, Gilead Sciences, Inc., Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Speaker: AbbVie, AstraZeneca, BeiGene, Gilead, Incyte, Janssen, Kite Pharma, Lilly, Loxo Oncology, Inc., Roche. Research grant; AstraZeneca and BeiGene.
Tahla Munir, PhD, reported a financial interest/relationship or affiliation in the form of Advisor: Alexion Pharmaceuticals, AstraZeneca, BeiGene, Janssen, Roche, and Sobi. Speaker: AbbVie, Alexion Pharmaceuticals, AstraZeneca, Janssen, and Sobi.
The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP, hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Facebook Comments